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OBJECTIVES: Breast cancer is the most common malignant disease in Western
women. In the ONCOTYROL research center, a decision-analytic Breast Cancer
Outcomes & Policy (BCOP) model is being developed to evaluate the cost-effective-
ness of the new 21-gene assay that supports personalized decisions on adjuvant
chemotherapy. Model validation is essential to build confidence in the model re-
sults and to influence decision makers. Based on the new ISPOR-SMDM best prac-
tice recommendations, the process of model validation will be presented.
METHODS: The 21-gene assay was evaluated by simulating a hypothetical cohort
of 50year old women over a lifetime time horizon, adopting a societal perspective.
Main model outcomes were life-years gained, quality-adjusted life-years (QALYs)
gained and costs. Themajor focus of the presentation is on cross validation, i.e. the
comparison ofmodeling results between the discrete event simulation (DES) BCOP-
model and the Markov model of the THETA (Toronto Health Economics and Tech-
nology Assessment) Collaborative. Therefore, the BCOP-model has been populated
with the Canadian parameters of the THETA-model. RESULTS: Cross validation
started with comparison of model parameters related to the natural history of the
disease (undiscounted life years, number of breast cancer recurrences/deaths).
Thereafter, quality of life and cost outcomes were compared. The comparison
included point estimates of the outcomes of the deterministic analysis of the
Markovmodel aswell as the probabilistic runwith theDES results and combination
(ICERs). The absolute differences of expected life years gained for women after
surgery ranged from -0.35 to 0.43 years depending on the treatment strategy for
specific risk groups. For the probabilistic analysis, confidence intervals as well as
distributions of model outcomes were compared. CONCLUSIONS: Cross model
validation is a suitable approach to identify and correct modeling errors and to
explain remaining differences of modeling results.
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OBJECTIVES: Treatments for Alzheimer’s disease (AD) have currently been proved
for effectiveness but the selection needs to determine whether the clinical benefits
justify their additional costs. This study aimed to evaluate the cost-effectiveness of
donepezil treatment of mind to moderate AD compared with usual care in the
perspective of provider and society. METHODS: A Markov model composed of 4
health states (mild, moderate, severe, and death) was constructed to extrapolate
the results over a 5-year period. The study included costs of donepezil, costs of
comorbidity treatment, and costs of informal care. Effectiveness was measured in
terms of quality-adjusted life year (QALY). Cost and utility data were directly col-
lected from Thai AD population, but transition probabilities and the effect of done-
pezil were derived from literature review. All costs and effects were discounted at
3% per annum. One-way and probabilistic sensitivity analyses were performed.
RESULTS: The results demonstrated that with the threshold level of Thai 1GPD per
capita (approximately 148,000 Baht/QALY in 2011), donepezil was not a cost-effec-
tive treatment for mild or moderate AD for both societal (incremental cost-effec-
tiveness ratio (ICER)  284,473 Baht/QALY) and provider perspectives (ICER 
369,148 Baht/QALY). The resultswere very sensitive to utility value and the effect of
donepezil. Donepezil became more cost-effective than usual care when the will-
ingness to pay level increased to at least 155,000 and 375,000 Baht/QALY for societal
and provider perspectives respectively. CONCLUSIONS:With a limited health care
resources, using donepezil for the treatment of AD might not be cost-effective in
Thai context.
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OBJECTIVES: Chronic kidney disease (CKD) is a common and growing global health
issue characterized by reduced glomerular filtration rate (GFR, mLs/min/1.73m2).
While investigators have used short-term changes in GFR as an endpoint, the re-
lationship between this endpoint and long-term outcomes has not been reported.
The objective herewas to estimate andquantify this relationship in order to predict
the timing and number of cases of end-stage renal disease (ESRD) occurring over
the lifetime of a cohort of hypothetical CKD patients with moderate and advanced
disease.METHODS:We constructed a three-state Markov model (functioning kid-
ney, ESRD, and death) with an annual cycle length to project GFR on long-term
health outcomes. Using published GFR-specific risk equations, and adjusting for
confounders, we estimated the probability of ESRD (assumed at GFR10) and time
to death according to baseline GFR categories defined by the United States (U.S.)
Kidney Disease Outcomes Quality Initiative. Included in the modeling was a term
representing two types of CKD patients characterized by “slow” and “fast”
progression. RESULTS: For CKD patients aged 55 years, projected lifetime proba-
bilities of progressing to ESRD were: 0.05, 0.25, 0.81, and 0.97 in GFR categories
45-59, 30-44, 15-29, and15, respectively. Projectedmean survival timeswere: 16.7,
13.7, 11.4, and 9.4 years for the sameGFR categories. Themodelwas calibratedwith
mortality data reported by the U.S. Renal Data System. CONCLUSIONS: The model
can project the potential impact of baseline GFR on long-term outcomes in CKD.
Estimating the time spent in GFR categories allows quantification of the entire
trajectory of CKDuntil renal failure or death. In future, themodelmay be refined by
incorporating additional empirical data describing longer-term follow-up.
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OBJECTIVES: To demonstrate if a nationally representative panel dataset can be
used to evaluate if quality of life (QoL) impacts are associated with changes in body
mass index (BMI). The aim was to estimate the utility increments (or decrements)
associated with weight loss (or gain) for application in economic evaluations of
obesity interventions. METHODS: Data from the Household, Income and Labour
Dynamics in Australia survey (HILDA) was used in the analysis. HILDA is a house-
hold-based panelwith 17,209 individuals from6,987 households collected annually
since 2001. This survey uses the SF-36 and the transformed SF-6D utility weight to
capture quality of life. Currently, there are 5 waves providing information on BMI.
The panel nature of the data was exploited with econometric techniques to show
the effect of changes in BMI (between different BMI classification groups) on quality
of life. RESULTS: The results demonstrated that being under-weight, over-weight
or obese is associated with reduced quality of life. When adjusting for other ex-
planatory variables, only the association between the obese category and dimin-
ished quality of life remained. The results from the panel data identified that only
those who remain severely obese over time experience significant reductions in
quality of life. Movements between other BMI categories were not associated with
significant impacts on quality of life. CONCLUSIONS: Economicmodels that assess
the cost-effectiveness of obesity interventions using cross-sectional data may
overestimate the QoL gain following a reduction in BMI. This could lead to non-
optimal policy oriented decisions. Population panel datasets may provide a better
estimate. Using econometric techniques alongside traditional cost-effectiveness
models offers a richer avenue of obtaining model inputs and more certainty in
regards to quantifying gains and losses in QoL.
PRM20
CONSTRUCTION OF THE MARKOV MODEL FOR HEPATITIS B VIRUS RELATED
DISEASES IN JAPAN
Yoda T, Yoshioka A, Suzue T, Hirao T
Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan
OBJECTIVES: Hepatitis B virus (HBV) is estimated to infect 350 million people all
over the world. Most infection with HBV do not induce clinical liver disease, while
less than 30% of them develop severe liver disease. We do not know, however, the
approximate number of the annual newly HBV infection and/or HBV development
in Japan. Then, we make Markov model with HBV infection and estimate annual
probability to disease development.METHODS:We reviewed clinical research pa-
per related to HBV infection published in Japan until December 2011. To research
Japanese original data, we used ‘Igaku Chuo Zasshi’ (Japanese medical journals
database), and JapaneseMinistry of Health, Labour andWelfare research database.
We then extracted some parameters (e.g., patients outcome, treatment, time hori-
zon) and calculated annual probability of disease development. RESULTS: We
made HBV infection model and estimate annual probability to disease develop-
ment from 22 eligible Japanese research papers and reports. The HBV Markov
model started from HBs antigen negative, then HBV infection, divided into 2 col-
umns (asymptomatic career, acute hepatitis) and so on. Each columns annual
probability were detected from clinical trial data in Japan. CONCLUSIONS: We
estimated HBV infection and related diseases progress probability by one-year in
Japan.Wewill estimate the cost of each diseases treatment, patient’s quality of life,
and then we will make Japanese HBV Markov model near future.
RESEARCH ON METHODS - Patient-Reported Outcomes Studies
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OBJECTIVES:A reliable and validmeasure is essential to evaluating and enhancing
patient medication adherence. There is no validated patient-reported medication
adherence measure in Singapore. This study aimed to validate the 8-item Morisky
Medication Adherence Scale (MMAS) in patients taking warfarin in Singapore.
METHODS: A cross-sectional survey was conducted in a convenient sample of 174
patients taking warfarin at an anticoagulation clinic in Singapore in 2011. Socio-
demographics and International Normalized Ratio (INR) valueswere obtained from
patient interview and hospital databases. Respondents completed the MMAS in
English or Chinese depending on their preference. The scale scores ranged from 0
to 8, with higher scores indicating better medication adherence. Reliability was
assessed using Cronbach’s alpha. Criterion-related validity was examined by relat-
ing the MMAS score to warfarin refill rate. Construct validity was examined via
factor analysis and hypothesis testing. RESULTS: The reliability of the MMAS was
moderate (Cronbach’s alpha  0.56). The scale scores were associated with warfa-
rin refill rates (p  0.02). Confirmatory factor analysis showed that the eight items
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